Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-06-28
2009-06-02
Bernhardt, Emily (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S227800, C514S252190, C514S253110, C514S254030, C544S058200, C544S060000, C544S121000, C544S295000, C544S364000, C544S367000
Reexamination Certificate
active
07541359
ABSTRACT:
Certain N-heteroarylpiperazinyl urea compounds of Formula (I), as defined in the specification, are described, which are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity. Thus, the compounds may be administered to treat, e.g., anxiety, pain, inflammation, sleep disorders, eating disorders, or movement disorders (such as multiple sclerosis).
REFERENCES:
patent: 6096784 (2000-08-01), Lerner et al.
patent: 6462054 (2002-10-01), Boger
patent: 2004/0220191 (2004-11-01), Schwink et al.
patent: 2005/0032747 (2005-02-01), Bartolini et al.
patent: 2006/0089344 (2006-04-01), Abouabdellah et al.
patent: 2006/0173184 (2006-08-01), Apodaca et al.
patent: 2006/0293310 (2006-12-01), Abouabdellah et al.
patent: 2007/0021403 (2007-01-01), Abouabdellah et al.
patent: 2007/0021405 (2007-01-01), Abouabdellah et al.
patent: 2007/0021424 (2007-01-01), Abouabdellah et al.
patent: 2007/0027141 (2007-02-01), Abouabdellah et al.
patent: 2008/0108629 (2008-05-01), Kamboj et al.
patent: 2008/0139565 (2008-06-01), Campbell et al.
patent: 2008/0312226 (2008-12-01), Matsumoto et al.
patent: 2854633 (2004-11-01), None
patent: 2864080 (2005-06-01), None
patent: 2865205 (2005-07-01), None
patent: 2866884 (2005-09-01), None
patent: 2866885 (2005-09-01), None
patent: 2866888 (2005-09-01), None
patent: 48010160 (1973-03-01), None
patent: 11139969 (1999-05-01), None
patent: WO 96/09817 (1996-04-01), None
patent: WO 96/21648 (1996-07-01), None
patent: WO 97/49667 (1997-12-01), None
patent: WO 98/37077 (1998-08-01), None
patent: WO 99/42107 (1999-08-01), None
patent: WO 02/08221 (2002-01-01), None
patent: WO 2004/033652 (2004-04-01), None
patent: WO 2006/054652 (2006-05-01), None
patent: WO 2006/085108 (2006-08-01), None
patent: WO 2006/088075 (2006-08-01), None
Testa et al. Pure Appl. Chem. vol. 76, p. 907-914 (2004).
Matsumoto et al. Chemical Abstracts, vol. 145, No. 8189 (abstract for WO 2006054652, May 26, 2006) (2006).
Fox et al. Expert Opin.Investig.Drugs, vol. 14, p. 695-703 (2005).
Teare et al.Expert Opin.Investig.Drugs, vol. 14, p. 859-869 (2005).
Cravatt et al. Current Opinion in Chemical Biology, vol. 7, p. 469-475 (2003).
Baker et al., “Cannabinoids controls spasticity and tremor in a multiple sclerosis model,”Nature2000, 404, 84-87.
Baker et al., “Endocannabinoids control spasticity in a multiple sclerosis model,”FASEB J.2001, 15(2), 300-302.
Boger et al., “Trifluoromethyl ketone inhibitors of fatty acid amide hydrolase: A probe of structural and conformational features contributing to inhibition,”Bioorg. Med. Chem. Lett.1999, 9, 265-270.
Boger et al., “Exceptionally potent inhibitors of fatty acid amide hydrolase: The enzyme responsible for degradation of endogenous oleamide and anandamide,”Proc. Natl. Acad. Sci.USA 2000, 97(10), 5044-5049.
Boger et al., “α-Keto heterocycle inhibitors of fatty acid amide hydrolase: Carbonyl group modification and α-substitution,”Bioorg. Med. Chem. Lett.2001, 11, 1517-1520.
Cravatt et al., “Chemical characterization of a family of brain lipids that induce sleep,”Science1995, 268(5216), 1506-1509.
Cravatt et al., “Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides,”Nature1996, 384(6604), 83-86.
Cravatt et al., “Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase,”Proc. Natl. Acad. Sci.USA 2001, 98(16), 9371-9376.
Devane et al., “Isolation and structure of a brain constituent that binds to the cannabinoid receptor,”Science1992, 258(5090), 1946-1949.
Goya et al., “Recent advances in cannabinoid receptor agonists and antagonists,”Exp. Opin. Ther. Patents2000, 10(10), 1529-1538.
Kathuria et al., “Modulation of anxiety through blockade of anandamide hydrolysis,”Nat. Med.2003, 9(1), 76-81.
Kirkham et al., “Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: stimulation of feeding by 2-arachidonyl glycerol,”Br. J. Pharmacol.2002, 136, 550-557.
Lambert et al., “The Palmitoylethanolamide and Oleamide Engmas: Are These Two Fatty Acid Amides Cannabimimetic?”Curr. Med. Chem.1999, 6, 757-773.
Lambert et al., “The palmitoylethanolamide family: A new class of anti-inflammatory agents?”Curr. Med. Chem.2002, 9(6), 663-674.
Mendelson et al., “The hypnotic actions of the fatty acid amide, oleamide,”Neuropsychopharmacology2001, 25(S5), S36-S39.
Piomelli, “The molecular logic of endocannabinoid signalling,”Nat. Rev. Neurosci.2003, 4(11), 873-884.
Robson, “Therapeutic aspects of cannabis and cannabinoids,”Br. J. Psychiatry2001, 178, 107-115.
Rodriguez de Fonseca et al., “An anorexic lipid mediator regulated by feeding,”Nature2001, 414, 209-212.
Svendsen et al., “Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial,”Br. Med. J.2004, 329(7460), 253-260.
Ueda et al., “Purification and characterization of an acid amidase selective for N-palmitoylethanolamine, a putative endogenous anti-inflammatory substance,”J. Biol. Chem.2001, 276(38), 35552-35557.
CAS No. 681136-29-8, Catalog No. HAN 00375, 2005.
CAS No. 681136-27-6, Catalog No. HAN00373, 2005.
CAS No. 681136-26-5, Catalog No. HAN00372, 2005.
Apodaca Richard
Breitenbucher J. Guy
Pattabiraman Kanaka
Seierstad Mark
Xiao Wei
Atkins Michael J.
Bernhardt Emily
Janssen Pharmaceutica N.V.
LandOfFree
N-heteroarylpiperazinyl ureas as modulators of fatty acid... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with N-heteroarylpiperazinyl ureas as modulators of fatty acid..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and N-heteroarylpiperazinyl ureas as modulators of fatty acid... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4108134